两天两笔重磅交易:GLP-1战场风云突变,巨头加速“买买买”

21世纪经济报道
Feb 26

21世纪经济报道记者季媛媛2026年春节后,全球代谢病药物研发领域显得格外躁动。2月24日,辉瑞中国与杭州先为达生物共同宣布达成战略合作,辉瑞获得新一代偏向型GLP-1受体激动剂埃诺格鲁肽注射液在中国大陆的独家商业化权益,交易总额最高可达4.95亿美元。仅仅一天之后的2月25日,丹麦巨头诺和诺德宣布与美国生物科技公司Vivtex达成一项价值高达21亿美元的合作协议,旨在开发用于肥胖症和糖尿病的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10